# Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study

> **NCT04801758** · NA · COMPLETED · sponsor: **HIV Vaccine Trials Network** · enrollment: 18 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **OTHER:** Analytical Treatment Interruption

## Key facts

- **NCT ID:** NCT04801758
- **Lead sponsor:** HIV Vaccine Trials Network
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-22
- **Primary completion:** 2024-07-22
- **Final completion:** 2024-07-22
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-04-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04801758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04801758, "Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04801758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*